Anson Funds Management’s BioAtla BCAB Stock Holding History

Anson Funds Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-92,021	Closed	-$2.72M	–	128
2024 Q4	$2.72M	Buy	+92,021	New	+$7.72M	0.27%	61

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Anson Funds Management's BCAB Position: Q1 2025 in Review

Anson Funds Management sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 92,021 shares — an estimated $2.72M sold.

Anson Funds Management first reported a position in BCAB in Q4 2024 and held it in 1 quarter. The position peaked at $2.72M in Q4 2024. 42 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

Anson Funds Management reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
Anson Funds Management sold 92,021 BioAtla shares in Q1 2025, an estimated $2.72M.
Anson Funds Management first reported a position in BioAtla in Q4 2024 and held it in 1 quarter.
Anson Funds Management's BioAtla position peaked at $2.72M in Q4 2024.
42 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Anson Funds Management's 13F filing for Q1 2025, filed 14 May 2025.